抗程序性死亡蛋白1（PD-1）免疫疗法联合序贯受累部位放疗用于多次预处理的难治性霍奇金淋巴瘤治疗
Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.
作者信息
Quéro L, Gilardin L, Fumagalli I, Martin V, Guillerm S, Bauduceau O, Kirova Y M, Hennequin C, Brice P
机构信息
Radiation oncology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France.
Department of haemato-oncology, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France.
出版信息
Cancer Radiother. 2019 Apr;23(2):132-137. doi: 10.1016/j.canrad.2018.05.002. Epub 2019 Feb 4.
The purpose of this study was to assess efficacy and tolerance of anti-programmed death (PD)-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma. In this case series, we reported the outcome of four heavily pretreated patients with refractory Hodgkin lymphoma treated by anti-PD-1 immunotherapy and involved site radiation therapy. After a median follow-up of 13-month, all patients were alive with complete metabolic response. After radiotherapy, all four patients experienced lung toxicity, which was resolved after antibiotherapy with or without corticosteroid treatment. Anti-PD-1 immunotherapy followed by involved-site radiotherapy is feasible and showed very encouraging results in heavily pretreated patients.
本研究的目的是评估抗程序性死亡（PD）-1免疫疗法联合序贯受累部位放疗在预处理严重的难治性霍奇金淋巴瘤中的疗效和耐受性。在这个病例系列中，我们报告了4例预处理严重的难治性霍奇金淋巴瘤患者接受抗PD-1免疫疗法和受累部位放射治疗的结果。中位随访13个月后，所有患者均存活且达到完全代谢缓解。放疗后，所有4例患者均出现肺部毒性，在使用或不使用皮质类固醇治疗的抗生素治疗后毒性得到缓解。抗PD-1免疫疗法后进行受累部位放疗是可行的，并且在预处理严重的患者中显示出非常令人鼓舞的结果。
Zotero 插件